BigHat

BigHat Biosciences designs safer, more effective antibody therapies for patients using machine learning and synthetic biology. Its Milliner platform integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies, synthesizing, purifying, and characterizing hundreds of recombinant antibodies in a weekly workcell. The San Mateo company partners with strategic biopharma organizations, including Lilly and Johnson & Johnson, to tackle complex protein therapeutic design challenges and advance next-generation treatments for infections, cancers, and other intractable diseases.